Yanbin Yu

TL;DR: In this paper, the expression cloning and characterization of GDNFR-α, a novel glycosylphosphatidylinositol-linked cell surface receptor for glial cell line-derived neurotrophic factor (GDNF), was reported.

TL;DR: The receptor for glial cell line-derived neurotrophic factor (GDNF) consists of GFRα-1 and Ret, and it is reported that neurturin can bind to either GFR α-1 or G FRα-2, a novel receptor related to GFRβ, suggesting that GFRs mediate the action of GDNF family ligands in vivo.

TL;DR: There are multiple mechanisms regulating the interaction between Ret and the α-receptors that mediates the effects of GDNF family trophic factors on the survival and differentiation of cells and on neuron–target interactions in the nervous system.

TL;DR: The generation and characterization of two distinct monoclonal antibodies, G‐90 and B‐1531, specific to glial cell line‐derived neurotrophic factor (GDNF), and the data suggest that the NH2 terminus of GDNF is not critical for activity.

TL;DR: This work has established a novel and non-radioactive bioassay system using branched DNA (bDNA) technology for detecting protein-therapeutic neutralizing antibodies in patient serum that measures the variations of target gene expression that reflect the biologic effect of the therapeutic agent and the capability of the antibodies, if present, to neutralize the therapeutics.